Colonoscopy-Related Factors May Predict Cancer Risk

Published Online: Tuesday, September 18, 2012
Follow Pharmacy_Times:

A study from the August 21, 2012, issue of Annals of Internal Medicine shows that incomplete polyp removal and the lack of a follow-up colonoscopy within 5 years of initial polyp detection is strongly associated with risk for subsequent development of colorectal cancer.

Scientists examined 155 patients from a previously published population-based, case-control study who developed colon cancer within 10 years of polyp removal. They were compared with 260 control participants who also had polyp removal but did not develop cancer. Case and control participants were compared according to colonoscopy and polyp-related factors that could affect the development of cancer, such as the presence of multiple adenomas, polyp characteristics, and histologic findings.

Based on odds ratios and attributable fractions derived by using multiple logistic regression and the Levin formula, they determined that colonoscopy-related factors are more important than polyp characteristics in the calculation of colorectal cancer risk. Overall, nearly twice as many colorectal cancer cases were due to colonoscopy-related rather than polyp-related characteristics (41.1% versus 21.7%).

Study author Hermann Brenner, MD, of the German Cancer Research Center, and colleagues wrote, “These patterns underline the importance of efforts to optimize procedural aspects of colonoscopy, such as enduring complete removal of all polyps."



Related Articles
Since patients with Barrett’s esophagus seem to progress to cancerous stages faster than others, health care professionals might perceive that controlling acid reflux would prevent the transition.
The FDA announced today that it has expanded the indication of Bristol-Myers Squibb’s anticancer medication nivolumab (Opdivo) to include the treatment of patients with metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$